AAD 2026Abstract 72711
A phase 3 study assessing the efficacy, safety and tolerability of up to two 5-day treatment courses of tirbanibulin 1% ointment in patients with actinic keratosis (AK) over a treatment field up to approximately 100 cm2
Welzel J, Szepietowski JC, Pulido CF, Pellacani G, Mosterd K, Otero R, Pérez Fierro AM, Malvisi L, Siddall H, Pau-Charles I, Dirschka T
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Skin cancer & tumors
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.095 · Not in PubMed: details from Crossref